Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic HPV-specific CD4+ T lymphocytes

A preparation of allogeneic T lymphocytes, collected from a haploidentical donor of the patient after vaccination with human papillomavirus (HPV) vaccine series, and depleted of CD8+ lymphocytes, with potential antiviral and antineoplastic activities. Upon administration, allogeneic HPV-specific CD4+ T lymphocytes may induce selective toxicity in HPV-positive cancer cells and other HPV-infected cells. HPV is associated with various cancer cell types. The depletion of CD8+ lymphocytes from the donor cell preparation may lower the risk of graft-versus-host disease (GvHD).

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	allogeneic HPV-specific CD4+ T cells allogeneic HPV-specific CD4+ T cells

allogeneic HPV-specific CD4+ T lymphocytes

Search NCI's Drug Dictionary